share_log

Cantor Fitzgerald Initiates Coverage On Verve Therapeutics With Neutral Rating, Announces Price Target of $21

Benzinga Real-time News ·  Feb 1, 2023 07:57

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Neutral rating and announces Price Target of $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment